HC Wainwright Forecasts Higher Earnings for Aura Biosciences

Aura Biosciences, Inc. (NASDAQ:AURA) – Analysts at HC Wainwright boosted their FY2024 earnings estimates for Aura Biosciences in a report issued on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will earn ($1.69) per share for the year, up from their prior forecast of ($1.71). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2025 earnings at ($1.94) EPS and FY2026 earnings at ($2.06) EPS.

AURA has been the topic of a number of other reports. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Scotiabank lifted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research boosted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Stock Down 5.0 %

NASDAQ:AURA opened at $9.47 on Monday. The stock has a market cap of $473.03 million, a PE ratio of -5.47 and a beta of 0.33. The business’s 50-day simple moving average is $9.82 and its two-hundred day simple moving average is $8.54. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, CFO Julie B. Feder sold 25,131 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 15.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Aura Biosciences

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after acquiring an additional 39,379 shares in the last quarter. Barclays PLC grew its holdings in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Aura Biosciences in the 3rd quarter valued at $1,037,000. State Street Corp raised its stake in Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after acquiring an additional 26,841 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after acquiring an additional 3,612 shares during the period. 96.75% of the stock is currently owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.